Avanafil is a highly selective phosphodiesterase type 5 (PDE5) inhibitor licensed from Mitsubishi Tanabe Pharma.
The study evaluated the safety and efficacy of avanafil as a treatment of ED following bilateral, nerve-sparing and radical prostatectomy.
The primary endpoints of the study were improvement in erectile function as measured by the Sexual Encounter Profile (both SEP2 and SEP3) and improvements in the EF-Domain of the IIEF score; secondary endpoints included patient satisfaction with erections and with sexual experience.
The results of the trial showed successful intercourse as early as 15 mins after the administration of avanafil.
An investigator of the study John Mulhall said the trial met all the primary endpoints and detailed results of the study will be presented during the upcoming Cancer Survivorship Symposium to be held in Washington DC.
With the exception of certain Asian Pacific Rim countries, VIVUS owns worldwide development and commercial rights to avanafil.